Autopsy report · NCT04394624

Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)

“Sponsor decision, the decision is not related to any safety concern.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 4 years 2 months before it stopped.
• 31 participants enrolled.
• Results were posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Sanofi

Sponsor type

Industry

Conditions

Non-small Cell Lung Cancer Metastatic

Interventions

SAR408701; ramucirumab; pembrolizumab

Participants

31

Sites

13

Countries

Bulgaria, Czechia, Portugal, South Korea, Spain, United States

Trials that died the same way

• REGENETEN™ Bioinductive Implant System in Full-thickness Tears
  “Sponsor decision not related to safety.” (95% match in meaning)
• Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program
  “Sponsor decision not related to safety concerns” (91% match in meaning)
• Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
  “This was a sponsor decision and was not a consequence of any safety concern” (87% match in meaning)
• Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
  “Sponsor decision not related to safety reasons” (87% match in meaning)
• A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
  “Sponsor's decision, no safety concerns.” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.